REG - Oxford Nanopore Tech - London Calling Technology Update

Oxford Nanopore TechnologiesAnnouncement

23/05/2024 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW6274Pa&default-theme=true

RNS Number : 6274P  Oxford Nanopore Technologies plc  23 May 2024

Oxford Nanopore Technologies plc

London Calling Technology Update

Announcements highlighted breakthrough technology performance and updates to
Oxford Nanopore's IVD pipeline at annual customer conference

23 May 2024

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the
"Company"), the company delivering a new generation of nanopore-based
molecular sensing technology, presented breakthrough performance data and new
platform updates at the Company's annual London Calling customer conference,
held between 21 and 24 May 2024. During the sold-out event, with more than
5,500 registered on-line and in-person participants, the Company also provided
updates to its clinical product pipeline, unveiling a new roadmap for its
first IVD product ahead of its first clinical and biopharma day on Friday.

Technology updates included:

·      Delivering increasingly rich, high performance multiomic data:
The update focused on improved performance on accuracy, delivering complete
genomes with nanopore-only Telomere-to-Telomere (T2T) sequencing, and
full-length chromosomes in a single read, illustrated by successful T2T reads
of four yeast chromosomes as proof of concept.

·      Improving direct RNA sequencing to support breakthrough science
and biopharma workflows: higher accuracy and output for direct RNA sequencing
alongside the example of integrated, real-time quality control (QC) test for
mRNA vaccines.

·      Pipeline updates, enabling ultra-high output and accessible,
distributed sequencing for anyone, anywhere: with the MinION Mk1D entering
early access, continued progression with TraxION, enabling portable library
prep in the field, the Voltage chip for ultra-rapid whole genome sequencing
(WGS) and the new prototype of Oxford Nanopore's smallest sequencer to date -
the SmidgION  - which was on display at the event.

 

A written summary and a video replay of the technology talk can be accessed on
the Oxford Nanopore website here
(https://nanoporetech.com/news/oxford-nanopore-announces-breakthrough-technology-performance-to-deliver-complete-human-genomes-and-richer-multiomic-data-in-london-calling-tech-update)
.

 

This morning, the Company will present a product review including an update on
progress to its regulated product pipeline. In addition to locked-down Q line
devices, the GridION is expected to meet ISO 13485 standards in 2025 and the
Company will seek CE-IVD certification in the EU after that. The device will
be available for specified partners only. The GridION Q-Line product range is
on track to launch shortly in Q3-2024, as previously announced.

 

Alongside the technology updates the Company will also provide more details at
its first clinical and biopharma day on Friday.

 

 ENDS 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:      ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:           media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology for
real-time, high-performance, accessible and scalable analysis of DNA and RNA.
The technology is used in more than 120 countries to understand the biology of
humans and diseases such as cancer, plants, animals, bacteria, viruses and
whole environments. Oxford Nanopore Technologies products are intended for
molecular biology applications and are not intended for diagnostic
purposes. www.nanoporetech.com

 

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, the COVID-19 pandemic, delays in our
receipt of components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products or
accelerated adoption of pathogen surveillance. These or other uncertainties
may cause our actual future results to be materially different than those
expressed in our forward-looking statements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKNBQABKKAPB